gs2-02: "elacestrant, an oral selective estrogen receptor degrader (serd), vs investigator’s..."
Published 1 year ago • 660 plays • Length 20:37Download video MP4
Download video MP3
Similar videos
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
2:03
emerald: elacestrant vs. soc for patients with er her2- metastatic breast cancer
-
0:49
san antonio breast cancer symposium 2022 highlights
-
17:34
gs2 03. discussant
-
13:53
gs2-01: "overall survival subgroup analysis by metastatic site from the phase3 monaleesa-2..."
-
0:58
dr. esserman discusses the i-spy 2 trial in breast cancer
-
0:52
first-line camizestrant for er /her2- advanced breast cancer
-
16:51
dr. jan liefers gerrit | san antonio breast cancer symposium 2022 | general session
-
1:05
cambria 1: camizestrant er /her2- early breast cancer
-
3:01
assessing elacestrant in ctdna-positive patients with er breast cancer
-
0:55
cambria-1: camizestrant vs standard endocrine therapy in breast cancer
-
0:56
the san antonio breast cancer symposium (sabcs) 2022
-
16:43
gs4 02 analysis of clinical outcomes and expression-based immune signatures by race in the i-spy 2
-
0:51
ember-2: preoperative imlunestrant for er /her2- early stage breast cancer
-
0:30
the role of serds in the treatment landscape of patients with er /her2- breast cancer
-
17:55
translational science forum: "heterogeneity in treatment outcomes for her2 breast cancer clinic..."
-
1:37
grhl2 controlled gene expression networks in luminal breast cancer
-
1:02:48
expanding treatment options in er /her2- breast cancer: serds, serms, sercas, and more